Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Adults with chronic or immunocompromising conditions have an elevated risk of invasive pneumococcal disease, yet their pneumococcal vaccination rates remain low.

Methods: This retrospective cohort study used the IBM MarketScan® Multi-State Medicaid database to examine pneumococcal vaccination uptake among adults 19-64 years of age with underlying conditions. Gompertz accelerated failure time model was used to examine factors associated with vaccination.

Results: In the study population of 108,159 adults, the vaccination rate was 4.1% after 1 year of follow-up and 19.4% after 10 years. The mean time from initial diagnosis to vaccination was 3.9 years. Adults aged 35-49 and 50-64 years (relative to 19-34) or those receiving an influenza vaccination were more likely to receive a pneumococcal vaccination. Adults with HIV/AIDS were more likely, while adults with chronic heart or lung disease, alcohol or tobacco dependence, or cancer were less likely to be vaccinated than adults with diabetes mellitus. Adults diagnosed by specialists were less likely to be vaccinated than those diagnosed by primary care providers.

Conclusions: The rates of pneumococcal vaccination among adults with Medicaid plans and underlying conditions were well under Healthy People Initiative targets. Insights into factors associated with vaccination can inform efforts to improve vaccination rates among this population.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2023.2226718DOI Listing

Publication Analysis

Top Keywords

pneumococcal vaccination
20
adults
10
vaccination
9
adults chronic
8
vaccination rates
8
underlying conditions
8
factors associated
8
vaccination adults
8
pneumococcal
6
vaccination coverage
4

Similar Publications

remains a leading respiratory pathogen for children and the elderly. In Taiwan, a national PCV13 catch-up vaccination programme for children began in March 2013. This study investigates the population structure and antimicrobial profiles of pneumococcal isolates in Taiwan from 2006 to 2022.

View Article and Find Full Text PDF

Vaccine Immunity Against Pneumococcus in Children With Sickle Cell Disease: A Retrospective Single-center Study.

Pediatr Infect Dis J

September 2025

Division of General Pediatrics, Department of Pediatrics, Gynecology and Obstetrics, Unit of Immunology, Vaccinology, and Rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

Background And Aims: Sickle cell disease (SCD) patients are at a higher risk of pneumococcal invasive diseases. Vaccination is the central strategy for protecting these children, along with penicillin prophylaxis. However, it is unclear how often these children should be revaccinated with pneumococcal vaccines.

View Article and Find Full Text PDF

causes otitis media and severe diseases including pneumonia, meningitis and bacteraemia. The rise of antimicrobial resistance (AMR) in , facilitated by mobile genetic elements (MGEs), complicates infection treatment. While pneumococcal conjugate vaccine (PCV) deployment has reduced disease burden, non-vaccine serotypes (NVTs) have increased and now cause invasive disease.

View Article and Find Full Text PDF

Splenic pseudocysts represent an uncommon condition in abdominal surgery, generally resulting from trauma, infection, or ischemic processes. Histologically, they are characterized by the absence of an epithelial lining; that is, they lack the inner layer of cells typically found in true cysts. Its clinical presentation is non-specific, commonly manifesting with abdominal pain, early satiety, or alterations in bowel habits, which lead to late or incidental diagnoses through imaging studies.

View Article and Find Full Text PDF

Background: SLE has increased risk of invasive pneumococcal disease due to immune dysregulation and immunosuppression. European Alliance of Associations for Rheumatology recommendations suggest sequential vaccination with conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23). However, data on immunogenicity of sequential vaccination in SLE are limited.

View Article and Find Full Text PDF